Identifying Risk Factors Associated With False-Negative Results in US-Guided Percutaneous Transthoracic Needle Lung Biopsy of Subpleural Pulmonary Lesions.

IF 2.3 3区 医学 Q3 ONCOLOGY Thoracic Cancer Pub Date : 2024-12-17 DOI:10.1111/1759-7714.15506
Jiawei Yi, Mengjun Shen, Junhui He, Runhe Xia, Xinyu Zhao, Yin Wang
{"title":"Identifying Risk Factors Associated With False-Negative Results in US-Guided Percutaneous Transthoracic Needle Lung Biopsy of Subpleural Pulmonary Lesions.","authors":"Jiawei Yi, Mengjun Shen, Junhui He, Runhe Xia, Xinyu Zhao, Yin Wang","doi":"10.1111/1759-7714.15506","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>This study aims to investigate the factors influencing false-negative results in ultrasound-guided percutaneous transthoracic needle lung biopsy results (US-PTLB).</p><p><strong>Materials and methods: </strong>This ambispective cohort study included patients with subpleural pulmonary lesions who underwent US-PTLB with benign pathological findings between April 2017 and June 2022 (retrospective cohort) and between July 2022 and October 2022 (prospective cohort). In the retrospective cohort, comparative and logistic regression analyses were performed to identify independent risk factors for false-negative biopsy results. Stratified analyses based on these risk factors were performed in the prospective cohort.</p><p><strong>Results: </strong>The retrospective cohort included 1747 (true-negative: false-negative, 1321:426) patients with negative biopsy results, which were analyzed by comparative and logistic regression analyses, and the results demonstrated that advanced age (> 56 years) (OR = 1.08, 95% CI: 1.07-1.09), small-sized lesions (< 3 cm) (OR = 1.80, 95% CI: 1.38-2.34), lesions with necrosis (OR = 3.00, 95% CI: 2.29-3.92), contrast-enhanced ultrasound (CEUS) showing hyper-enhancement (OR = 5.87, 95% CI: 4.09-8.42) or iso-enhancement (OR = 2.81, 95% CI: 2.05-3.83), and the presence of hemoptysis (OR = 11.82, 95% CI: 5.16-27.08) or pneumothorax (OR = 7.90, 95% CI: 2.89-21.58) during the puncture were independent predictors of false-negative US-PTLB results. The results of stratified analyses in the prospective cohort were consistent with the retrospective cohort.</p><p><strong>Conclusion: </strong>Risk factors associated with false-negative results included advanced age (> 56 years), small-sized lesion (< 3 cm), presence of necrosis in the lesion, CEUS showing hyper-enhancement or iso-enhancement of the lesion, and hemoptysis or pneumothorax during puncture.</p><p><strong>Trial registration: </strong>Number: ChiCTR2000029749.</p>","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":" ","pages":""},"PeriodicalIF":2.3000,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Thoracic Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/1759-7714.15506","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: This study aims to investigate the factors influencing false-negative results in ultrasound-guided percutaneous transthoracic needle lung biopsy results (US-PTLB).

Materials and methods: This ambispective cohort study included patients with subpleural pulmonary lesions who underwent US-PTLB with benign pathological findings between April 2017 and June 2022 (retrospective cohort) and between July 2022 and October 2022 (prospective cohort). In the retrospective cohort, comparative and logistic regression analyses were performed to identify independent risk factors for false-negative biopsy results. Stratified analyses based on these risk factors were performed in the prospective cohort.

Results: The retrospective cohort included 1747 (true-negative: false-negative, 1321:426) patients with negative biopsy results, which were analyzed by comparative and logistic regression analyses, and the results demonstrated that advanced age (> 56 years) (OR = 1.08, 95% CI: 1.07-1.09), small-sized lesions (< 3 cm) (OR = 1.80, 95% CI: 1.38-2.34), lesions with necrosis (OR = 3.00, 95% CI: 2.29-3.92), contrast-enhanced ultrasound (CEUS) showing hyper-enhancement (OR = 5.87, 95% CI: 4.09-8.42) or iso-enhancement (OR = 2.81, 95% CI: 2.05-3.83), and the presence of hemoptysis (OR = 11.82, 95% CI: 5.16-27.08) or pneumothorax (OR = 7.90, 95% CI: 2.89-21.58) during the puncture were independent predictors of false-negative US-PTLB results. The results of stratified analyses in the prospective cohort were consistent with the retrospective cohort.

Conclusion: Risk factors associated with false-negative results included advanced age (> 56 years), small-sized lesion (< 3 cm), presence of necrosis in the lesion, CEUS showing hyper-enhancement or iso-enhancement of the lesion, and hemoptysis or pneumothorax during puncture.

Trial registration: Number: ChiCTR2000029749.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
背景:本研究旨在探讨影响超声引导下经皮经胸针肺活检(US-PTLB)结果假阴性的因素:本研究旨在探讨影响超声引导下经皮经胸针肺活检(US-PTLB)结果假阴性的因素:这项前瞻性队列研究纳入了2017年4月至2022年6月期间(回顾性队列)和2022年7月至2022年10月期间(前瞻性队列)接受US-PTLB检查且病理结果为良性的胸膜下肺部病变患者。在回顾性队列中,进行了比较分析和逻辑回归分析,以确定活检结果假阴性的独立风险因素。在前瞻性队列中,根据这些风险因素进行了分层分析:结果:回顾性队列中纳入了 1747 例(真阴性:假阴性,1321:426)活检结果为阴性的患者,并对其进行了比较分析和逻辑回归分析,结果显示,高龄(> 56 岁)(OR = 1.08,95% CI:1.07-1.09)、小尺寸病变(结论:高龄和小尺寸病变是导致活检结果为阴性的主要风险因素:与假阴性结果相关的风险因素包括高龄(> 56 岁)、小面积病灶(试验登记:编号ChiCTR2000029749。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Thoracic Cancer
Thoracic Cancer ONCOLOGY-RESPIRATORY SYSTEM
CiteScore
5.20
自引率
3.40%
发文量
439
审稿时长
2 months
期刊介绍: Thoracic Cancer aims to facilitate international collaboration and exchange of comprehensive and cutting-edge information on basic, translational, and applied clinical research in lung cancer, esophageal cancer, mediastinal cancer, breast cancer and other thoracic malignancies. Prevention, treatment and research relevant to Asia-Pacific is a focus area, but submissions from all regions are welcomed. The editors encourage contributions relevant to prevention, general thoracic surgery, medical oncology, radiology, radiation medicine, pathology, basic cancer research, as well as epidemiological and translational studies in thoracic cancer. Thoracic Cancer is the official publication of the Chinese Society of Lung Cancer, International Chinese Society of Thoracic Surgery and is endorsed by the Korean Association for the Study of Lung Cancer and the Hong Kong Cancer Therapy Society. The Journal publishes a range of article types including: Editorials, Invited Reviews, Mini Reviews, Original Articles, Clinical Guidelines, Technological Notes, Imaging in thoracic cancer, Meeting Reports, Case Reports, Letters to the Editor, Commentaries, and Brief Reports.
期刊最新文献
Impact of DLL3 Expression as Prognostic Factor in Extensive Stage of Small Cell Lung Cancer Treated With First-Line Chemotherapy. A Case of Primary Lung Adenocarcinoma With Recurrent Brain Metastasis due to Transformation to Small Cell Carcinoma During Adjuvant Atezolizumab Therapy. EGFR, TP53, and CUL3 Triple Mutation in Non-Small Cell Lung Cancer and its Potentially Poor Prognosis: A Case Report and Database Analysis. Indocyanine Green Fluorescence Plus Blue Dye for Sentinel Lymph Node Biopsy in Patients Undergoing Neoadjuvant Chemotherapy for Breast Cancer: A Multicenter, Prospective Cohort Study. Exosomal PVRL4 Promotes Lung Adenocarcinoma Progression by Enhancing the Generation of Myeloid-Derived Suppressor Cell-Secreted TGF-β1.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1